A clinical study for people with migraine
September 3, 2019
Read More »
Satsuma Pharmaceuticals, Inc. Announces Proposed Initial Public Offering of Common Stock
September 3, 2019
Read More »
Satsuma Pharmaceuticals Announces Poster Presentations at the International Headache Congress
August 22, 2019
Read More »
Satsuma Pharmaceuticals Announces First Patient Dosed in EMERGE™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
July 8, 2019
Read More »
Satsuma Pharmaceuticals Announces Presentation of STS101 (Dihydroergotamine Nasal Powder) Phase 1 Trial Results at American Headache Society’s Annual Scientific Meeting
April 24, 2019
Read More »
Satsuma Pharmaceuticals Raises $62 Million in Series B Preferred Stock Financing
April 1, 2019
Read More »
Satsuma Pharmaceuticals to Present at Needham & Company 18th Annual Healthcare Conference
February 20, 2019
Read More »